Clinical trials
Relapsed Large B-cell Lymphoma clinical trials
Below are recruiting relapsed large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 237 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06517004RecruitingPhase 1
Study of JWCAR201 for relapsed or refractory large B-cell lymphoma
This trial tests a new cell therapy called JWCAR201 for people with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not responded to at least two prior treatments. The goal is to see if this treatment can help when standard options have stopped working.
ShanghaiAges 18 years+ - NCT06521255RecruitingPhase 3
New drug combo vs standard for relapsed DLBCL
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
BeijingAges 18 years+ - NCT03676504RecruitingPhase 1/Phase 2
CAR T cell therapy for relapsed CD19 blood cancers
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
HeidelbergAges 3 years+ - NCT06554600RecruitingPhase 2
Study of zanubrutinib plus polatuzumab, bendamustine, and rituximab for relapsed DLBCL
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
Hanzhou, ZhejiangAges 18–75 - NCT06479356RecruitingPhase 2
CAR T-cell therapy for relapsed large B-cell lymphoma
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05255354Recruiting
Testing blood cancer DNA monitoring during CAR-T treatment
This trial checks whether a blood test that looks for small amounts of cancer DNA can accurately track minimal residual disease (MRD) in lymphoma patients during CAR-T therapy. It may help doctors detect relapse earlier and better judge how well CAR-T is working.
Palo Alto, CaliforniaAges 18 years+ - NCT07775508RecruitingPhase 1
Car t cell therapy for relapsed or refractory b cell lymphoma
This trial tests a new treatment using your own immune cells, called CAR T cells, that are specially made to find and attack cancer cells in B-cell lymphoma. It may help if your lymphoma has come back or has not gone away after other treatments.
BeijingAges 18–75 - NCT07774572RecruitingPhase 1
Circular RNA study for B-cell blood cancers
This study looks at a new way to treat B-cell blood cancers that have not responded to other treatments or have come back. It tests a therapy that targets cancer cells using RNA, which is a molecule that helps make proteins in your body.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04332822RecruitingPhase 3
Testing mini-CHOP versus adding polatuzumab for lymphoma
This study compares two lymphoma treatments: mini-CHOP alone versus mini-CHOP plus a drug called polatuzumab vedotin. It aims to see which regimen works better and is tolerable for older or frail people with certain types of aggressive B-cell lymphoma.
AlburyAges 75 years+ - NCT07739654RecruitingPhase 3
Modified chemotherapy combo for relapsed large b-cell lymphoma
This study compares two chemotherapy regimens for people with diffuse large B-cell lymphoma that has returned or not responded to earlier treatment. The goal is to see if a modified version is as effective with fewer side effects.
Lahore, Punjab ProvinceAges 18 years+ - NCT07735533RecruitingPhase 1/Phase 2
UB-VV400 with rapamycin for large B-cell lymphoma
This trial tests an experimental treatment called UB-VV400 given with another drug, rapamycin, for people with large B-cell lymphoma that has not responded to standard therapy. The treatment targets a protein called CD22 on lymphoma cells and may help your immune system fight the cancer.
Nashville, TennesseeAges 18 years+ - NCT05348213RecruitingPhase 2
Targeted drugs plus R-ICE chemo for relapsed lymphoma
This Phase 2 trial studies targeted drugs combined with R-ICE chemotherapy in people with diffuse large B-cell lymphoma (DLBCL) that has come back or hasn’t responded. It may help shrink the lymphoma after prior treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07676877RecruitingPhase 1
Low-dose radiation before CAR-T therapy for large B-cell lymphoma
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
Columbus, OhioAges 18 years+ - NCT06678282Recruiting
Testing an investigational cell therapy for B-cell lymphoma or leukemia
This trial tests a new cell therapy (JY231) for people with B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or didn't respond to previous treatments. The therapy targets a marker on cancer cells called CD19 and aims to help your body fight the cancer.
Zhenzhou, HenanAges 18–75 - NCT06693973RecruitingEarly Phase 1
AcNK-Sup003 cell therapy for relapsed B-cell lymphoma
This early-phase trial tests a new immune cell treatment called AcNK-Sup003 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior therapy. The goal is to see if it is safe and effective.
Wuhan, HubeiAges 18 years+ - NCT07620314RecruitingPhase 1
Testing a new cell therapy for B-cell lymphoma
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07606937RecruitingEarly Phase 1
Automated CAR-T cell therapy for relapsed large B-cell lymphoma
This early-stage trial tests an automated version of axicabtagene ciloleucel (a CAR-T cell therapy) for large B-cell lymphoma that has come back or stopped responding to initial chemotherapy. CAR-T therapy uses your own immune cells, modified in a lab to fight cancer cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06716164RecruitingEarly Phase 1
Experimental car-t cell therapy for relapsed b-cell lymphoma
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hangzhou, ZhejiangAges 19–70 - NCT07570823RecruitingPhase 3
SCTB35 Plus Chemotherapy for Relapsed Lymphoma
This study tests a new drug called SCTB35 combined with two common chemotherapy drugs (gemcitabine and oxaliplatin) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatment. The goal is to see if this combination is safe and helps shrink the cancer.
BeijingAges 18–80 - NCT07570017RecruitingPhase 1
Rocbrutinib Plus Chemotherapy for Resistant B-Cell Lymphoma
This study tests whether combining a new drug called rocbrutinib with standard chemotherapy (R-GemOx) works better for patients whose diffuse large B-cell lymphoma (a type of blood cancer) has stopped responding to previous treatments. Researchers hope this combination may help patients who have limited options.
Guangzhou, GuangdongAges 18 years+ - NCT07548697RecruitingEarly Phase 1
Safety study of CT1182 for relapsed B-cell lymphoma
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
Wuhan, HubeiAges 18–75 - NCT06071871RecruitingPhase 2
A trial of 3 drugs before or after CAR-T for lymphoma
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
LondonAges 18 years+ - NCT07538635RecruitingPhase 2
CAR-T cells plus stem cell transplant for aggressive lymphoma
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
Hangzhou, ZhengjiangAges 18 years+ - NCT07528352RecruitingPhase 1
Radiation Plus Antibody Therapy for Difficult-to-Treat Lymphoma
This trial tests a combination of radiation therapy to specific tumor sites followed by a bispecific antibody (a type of immunotherapy that targets cancer cells). It's designed for people with diffuse large B-cell lymphoma that has not responded to or has come back after at least two prior treatments.
Salt Lake City, UtahAges 18 years+
Hear when a new Relapsed Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed large b-cell lymphoma?
- Yes. Clin2 currently lists 237 recruiting relapsed large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Diffuse Large B Cell Lymphoma Relapsed
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Relapsed or Refractory Large B-cell Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Large B-cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.